Document:

Exhibit
4.9

 

DESCRIPTION
OF THE REGISTRANT’S SECURITIES

REGISTERED
PURSUANT TO SECTION 12 OF THE SECURITIES

EXCHANGE
ACT OF 1934

 

Oragenics,
Inc. (“Oragenics,” “we,” “our,” or “us”) has one class of securities registered under
Section 12 of the Securities Exchange Act of 1934, as amended: our common stock.

 

DESCRIPTION
OF CAPITAL STOCK

 

The
following descriptions are summaries of the material terms that are included in our amended and restated articles of incorporation (as
amended) and our bylaws (as amended) as well as the specific agreements such descriptions relate to. This summary is qualified in its
entirety by the specific terms and provisions contained in our restated articles of incorporation, bylaws and the specific agreements
described herein, copies of which we have filed as exhibits to our Annual Report on Form 10-K and are incorporated herein by reference.

 

Overview

 

Authorized
Capital Stock

 

Our
authorized capital stock consists of 250,000,000 shares of common stock, par value $0.001, and 50,000,000 shares of preferred stock,
without par value.

 

Listing

 

Our
common stock is listed and principally traded on the NYSE American under the symbol “OGEN.”

 

Common
Stock

 

Voting

 

The
holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the shareholders.
Approval of an amendment of our articles of incorporation, a merger, a share exchange, a sale of all our property or dissolution must
be approved by a majority of all votes entitled to be cast. Such votes may be cast in person or by proxy as provided in Article I Section
8 of our bylaws. One third of our shares entitled to vote constitute a quorum for purposes of a meeting of our shareholders.

 

Dividends

 

Subject
to preferences that may be applicable to any outstanding preferred stock, the holders of our common stock are entitled to receive ratably
all dividends, if any, as may be declared from time to time by our Board of Directors out of the funds legally available.

 

In
the event of the liquidation, dissolution or winding up of the Company, the holders of our common stock are entitled to share ratably
in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding.
The common stock has no preemptive or conversion rights. There are no redemption or sinking fund provisions applicable to the common
stock. All outstanding shares of common stock are fully paid and non-assessable.

 

Rights
upon Liquidation

 

Upon
our liquidation, dissolution or winding-up, after payment in full of our liabilities and the amounts required to be paid to holders of
any outstanding shares of preferred stock, if any, all holders of our common stock, along with the holders of our Series A Convertible
Preferred Stock and Series B Convertible Preferred Stock on an “as if” converted basis, will be entitled to receive a pro
rata distribution of all of our assets and funds legally available for distribution.

 

    	 

    	 	 	 

    

 

Redemption
and Pre-Emptive Rights

 

No
shares of our common stock are subject to redemption or have preemptive rights to purchase additional shares of our common stock or any
of our other securities.

 

Fully
Paid and Non-assessable

 

All
of our outstanding shares of common stock are fully paid and non-assessable.

 

Preferred
Stock

 

Our
Board of Directors has the authority, without action by our shareholders, to designate and issue up to 50,000,000 shares of preferred
stock in one or more series or classes and to designate the rights, preferences and privileges of each series or class, which may be
greater than the rights of our common stock. These rights, preferences and privileges could include dividend rights, conversion rights,
voting rights, redemption rights, liquidation preferences, the number of shares constituting any class or series and the designation
of the class or series. Terms selected by our Board of Directors in the future could decrease the amount of earnings and assets available
for distribution to holders of shares of common stock or adversely affect the rights and powers, including voting rights, of the holders
of shares of common stock without any further vote or action by the stockholders. As a result, the rights of holders of our common stock
will be subject to, and may be adversely affected by, the rights of the holders of the Series A Convertible Preferred Stock, and Series
B Convertible Preferred Stock or any other preferred stock that may be issued by us in the future, which could have the effect of decreasing
the market price of our common stock. We have 16,017,000 shares of preferred stock issued and outstanding.

 

Transfer
Agent and Registrar

 

The
transfer agent and registrar of our common stock is Continental Stock Transfer & Trust Company, 1 State Street 30th Floor, New York,
New York 10004, telephone: (212) 509-4000.

 

Certain
Anti-Takeover Provisions

 

Florida
Law

 

We
are not subject to the statutory anti-takeover provisions under Florida law because in our articles of incorporation we have specifically
elected to opt out of both the “control-share acquisitions” (F.S. 607.0902) and the “affiliated transactions”
(F.S. 607.0901) statutes. Since these anti-takeover statutes do not apply to a corporation that has specifically elected to opt out of
such provisions, we would not be able to invoke the protection of such statutes in the event of a hostile takeover attempt.

 

Articles
of Incorporation and Bylaw Provisions

 

Our
articles of incorporation and bylaws contain provisions that could have an anti-takeover effect. These provisions include

 

	 	●	authorization
    of the issuance of “blank check” preferred stock that could be issued by our Board of Directors without shareholder approval
    and that may be substantially dilutive or contain preferences or rights objectionable to an acquiror; 
	 	 	 
	 	●	the
    ability of the Board of Directors to amend the bylaws without shareholder approval; 
	 	 	 
	 	●	vacancies
    on our Board may only be filled by the remaining Directors and not our shareholders; and 
	 	 	 
	 	●	requirements
    that only our Board, our President or holders of more than 10% of our shares can call a special meeting of shareholders. 

 

    	 

    	 	 	 

    

 

These
provisions in our articles of incorporation and bylaws could delay or discourage transactions involving an actual or potential change
in control of us, including transactions in which shareholders might otherwise receive a premium for their shares over their current
prices. Such provisions could also limit the ability of shareholders to approve transactions that shareholders may deem to be in their
best interests and could adversely affect the price of our common stock.

 

Registration
Rights

 

Series
A Preferred Stock Private Placement. Pursuant to the May 10, 2017 Registration Rights Agreement, we granted certain demand registration
rights and piggyback registration rights with respect to the shares of our Common Stock issuable upon conversion of the Series A Preferred
Stock and the exercise of the common stock warrants that were issued commensurate with the issuance of the Series A Preferred Stock.

 

Series
B Preferred Stock Private Placement. Pursuant to the November 8, 2017 Amended and Restated Registration Right Agreement, we granted
certain demand registration rights and piggyback registration rights with respect to the shares of our Common Stock issuable upon conversion
of the Series B Preferred Stock and the exercise of the common stock warrants that were issued commensurate with the issuance of the
Series B Preferred Stock.. The Amended and Restated Registration Rights Agreement amended the previous registration rights agreement
entered into in connection with our Series A Preferred Stock Financing in May 2017.Exhibit
10.6

 

	 	Amendment #2
to

Technology
License Agreement

BUSINESS CONFIDENTIAL
– PROTECTED B

 

THIS
IS AN AMENDING AGREEMENT (the “Agreement”)

	BETWEEN:
    NATIONAL RESEARCH COUNCIL OF CANADA	(called
    “NRC”)

a
Departmental Corporation”

forming
part of the Government of Canada, which corporation was created by

Act
of Parliament, R.S.C. 1985, c. N-15

whose
head office address is: 1200 Montreal Road, Ottawa, Ontario K1A 0R6 Canada

Human
Health Therapeutics (HHT) Research Centre located at: 

6100 Royalmount Avenue, Montreal, Quebec H4P 2R2 Canada

 

Scientific
contacts: Yves Durocher – Email: yves.durocher@cnrc-nrc.gc.ca

Freya
Vercauteren – Email: freya.vercauteren@cnrc-nrc.gc.ca

Business
contact: Alexandre Serrano – Email: alexandre.serrano@cnrc-nrc.gc.ca

 

	AND:	ORAGENICS,
    INC.	(called
    the “Licensee”)

a
corporation under the laws of the state of Florida, the United States of America

whose
address is: 4902 Eisenhower Boulevard – Suite 125- Tampa, Florida, 33634, U.S.A.

Contact:
Michael Sullivan – Email: msullivan@oragenics.com

 

(hereinafter
collectively referred to as “the Parties” and individually as a “Party”)

 

WHEREAS
the Parties entered into a Technology License Agreement signed by NRC on July 26, 2021 with NRC reference number A-0039781 and amendment
#1 signed by the NRC on September 2nd, 2021 with NRC reference number A-0041119 (together called the “Original Agreement”).

 

WHEREAS
as part of their continuous co-operation to enhance and provide effective vaccines to fight infectious diseases, the Parties agree
to extend the scope of the field of use of the Original Agreement.

 

IN
CONSIDERATION of the mutual covenants hereunder, the Parties agree as follows:

 

	 	1.	The
    Original Agreement shall be read with the amended terms stated below. With respect to all other terms, the Parties confirm the Original
    Agreement.
	 	 	 
	 	2.	The
    Parties agree that the following statement shall be added to the end of Section 5.2 of the Original Agreement:

 

For
clarity, the Licensee shall provide the NRC every six (6) months from the first submission of an IND to any regulatory authority, with
a detailed a report pertaining to the latest updates and outcomes arising out of Regulatory Approval. The NRC shall treat these reports
as the Licensee’s confidential information as per stated in Section 6.2 of the Original Agreement.

 

	 	3.	The
    Parties agree that Section 2.2 of the Original Agreement is hereby removed in its entirety and replaced by the following:

 

2.2
Field of Use: The Licensee shall not deal in any manner with the NRC Technology except as authorized under this Agreement for applications
within the Territory and within the authorized field of use, which is: protein subunit vaccines against diseases caused by coronaviruses
and any genetic variants thereof for sales worldwide.

 

	 	4.	The
    Parties agree that Annex B of the Original Agreement is hereby removed in its entirety and replaced by the Annex B in this Agreement.
	 	 	 
	 	5.	This
    Agreement may be executed in one or more counterparts and by the different parties hereto in separate counterparts, each of which
    when executed shall be deemed to be an original but all of which taken together shall constitute one valid and binding Agreement.
    A portable document format (PDF) copy of an executed counterpart signature page will be as valid as an originally executed counterpart
    for purposes of signing this Agreement.

 

    	NRC INTERNAL USE: HHT – PP&A	# A-0041785 (Orig. A-0039781)	Page 1 of 3

     

    

 

	 	Amendment
                                            #2 to

Technology
License Agreement

BUSINESS CONFIDENTIAL
– PROTECTED B

 

 

    	NRC INTERNAL USE: HHT – PP&A	# A-0041785 (Orig. A-0039781)	Page 2 of 3

     

    

 

	 	Amendment #2
to

Technology
License Agreement

BUSINESS CONFIDENTIAL
– PROTECTED B

 

ANNEX
B – List of Contractors

 

List
of Contractors

 

	1.	KBI
    Biopharma; 1450 Infinite Drive, Louisville, CO USA 80027
	2.	Experimur;
    4045 South Morgan Street, Chicago, IL USA 60609-2514
	3.	Biodextris;
    525 Boulevard Cartier O, Laval, QC, Canada H7V 3S8
	4.	Avid
    Bioservices; 2642 Michelle Drive Suite 200, Tustin, CA USA 92780
	5.	PPD;
    929 North Front Street, Wilmington, NC USA 28401-3331
	6.	Walter
    Reed Army Institute of Research (WRAIR); 503 Robert Grant Ave, Silver Spring, MD USA 20910
	7.	Berkshire
    Sterile Manufacturing; 480 Pleasant Street, Suite B201 Lee, MA USA 01238
	8.	Bioreliance;
    14920 Broschart Road, Rockville, MD USA 20850-3349
	9.	Charles
    River Laboratories; 251 Ballardvale Street Wilmington, MA USA 01887
	10.	KryoCal
    LLC (as Kryosphere); 14001 Weston Parkway Suite 106, Cary, NC USA 27513
	11.	Resilience
    Biotechnologies Inc., 2585 Meadowpine Blvd, Mississauga, ON L5N 8H9, Canada
	12.	Goodwin
    Biotechnologies Inc. 1850 NW 69th Ave, Plantation, FL 33313, United States
	13.	Bionova
    Scientific Inc. 3100 W Warren Ave, Fremont, CA 94538, United States

 

List
of Service Providers

 

		1.	Biodextris;
                                            525 Boulevard Cartier O, Laval, QC, Canada H7V 3S8

 

    	NRC INTERNAL USE: HHT – PP&A	# A-0041785 (Orig. A-0039781)	Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]